Expanding at a CAGR of 1.8%, the global Antimetabolite Drugs market is projected to increase from a valuation of US$ 5,504.3 Mn in 2021 to US$ 6,579.2 Mn by 2032.
“Upsurge in the usage of Antimetabolite Drugss in the cancer therapies and increasing healthcare expenditure will help the global Antimetabolite Drugs market to generate great revenue in the projected period.”
| Attributes | Details |
|---|---|
| Antimetabolite Drugs Market Value in 2021 | US$ 5,504.3 Million |
| Antimetabolite Drugs Market Value in 2032 | US$ 6,579.2 Million |
| Antimetabolite Drugs Market CAGR (2022 to 2032) | 1.8% |
Drugs that interfere with enzymes and their reactions that are necessary for DNA synthesis are known as antimetabolites. S-Phase is used to build new DNA molecules, antimetabolite interferes and slows the synthesis of pyrimidine and purine which induce the death of cells. Antimetabolites are useful in cancer treatment but are toxic to the normal cell.
Antimetabolites are folic acids and pyrimidine or purine equivalents. These molecules are one of the crucial chemotherapeutic agents and are characterized by low molecular weight molecules. As these compounds have a similar structure to molecules used in nucleic acid synthesis, these molecules are used for different cancer treatments, which include pancreatic cancer, breast cancer, leukaemia, gastro-intestinal cancer, and ovarian cancer.
The existence of Antimetabolite Drugs has a false impact on cell cycles as these drugs inhibit cell division and growth. Therefore, these drugs are commonly used as chemotherapeutics in various cancer cases. Besides cancer therapeutics, Antimetabolite Drugs have different applications such as antibiotics and trabeculectomy.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The rapid development in the fields of oncology and drug delivery is expected to show significant growth in the Antimetabolite Drugs market during the forecast period. Additionally, the increased government investments in cancer treatment and diagnosis, research, and initiative to create awareness about cancer are anticipated to drive the global Antimetabolite Drugs market growth.
Moreover, an increase in unhealthy habits such as smoking, and consumption of tobacco are common factors that can cause cancer. This, in turn, is projected to propel the growth of the Antimetabolite Drugs market. Furthermore, an increase in the spending on research and development for cancer research activities in biotechnology and pharmaceutical firms is expected to boost market growth.
Due to well-established research infrastructure and rising interest in research activities, North America dominated the Antimetabolite Drugs market and is expected to show the same growth in the forecast period. Owing to the increasing research on cancer therapeutic and government supported funding policies, Europe has shown high growth in the Antimetabolite Drugs market.
Followed by Europe, East Asia and South Asia is expected to show the rapid growth over the forecast period. This is due to the increased prevalence of cancer and the focus of the government on the development of the medical infrastructure.
Principal Consultant
Some of the key players operating in the Antimetabolite Drugs market are Parenteral Drugs Limited., Bristol-Myers Squibb Company, Merck & Co., Inc., Fresenius Kabi Oncology Limited, GlaxoSmithKline plc, Cadila Pharmaceuticals., CELON LABS, Sanofi, Eli Lilly and Company (Lilly), Novartis AG, and Teva Pharmaceutical Industries Ltd.
| Attributes | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2012 to 2021 |
| Market Analysis | US$ Million for Value |
| By Drug Class | Pyrimidine Compounds; Purine Compounds; Folate Antagonists; Demethylation Agents |
| By Route of Administration | Oral; Intravenous; Intramuscular |
| By Application | Cancer Therapeutic; Cardiac Therapeutic; Arthritis Therapeutic |
| By Distribution Channel | Retail Sales; Hospital Pharmacies; Retail Pharmacies; Drug Stores; Online Pharmacies |
| By Region | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Players | Parenteral Drugs Limited.; Bristol-Myers Squibb Company; Merck & Co., Inc.; Fresenius Kabi Oncology Limited; GlaxoSmithKline plc; Cadila Pharmaceuticals; CELON LABS; Sanofi SA; Eli Lilly and Company (Lilly); Novartis AG; Teva Pharmaceutical Industries Ltd. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global Antimetabolite Drugs market is anticipated to register a CAGR of 1.8% during the forecast period.
The top 3 players in the global Antimetabolite Drugs market are Parenteral Drugs Limited., Bristol-Myers Squibb Company, and Merck & Co.
Explore Healthcare Insights
View Reports
Antimetabolite Drugs Market
